Needham & Company analyst, Serge Belanger, reiterated his Buy rating on shares of Collegium Pharmaceutical (NASDAQ: COLL) after the FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE